Shahrigharahkoshan Shaghayegh, Gagnon Louis-Philippe, Mathieu Steve
Dermatology, Laval University, Quebec City, CAN.
Pathology, Laval University, Quebec City, CAN.
Cureus. 2021 Oct 24;13(10):e19005. doi: 10.7759/cureus.19005. eCollection 2021 Oct.
The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented event, and in order to control its spread and minimize its damages, all efforts are immediately mobilized. Mass vaccination is considered a promising solution to combat this universal issue. However, given the urgent need for vaccine production, some of the side effects may not have been presented during trials and will only appear during the mass vaccination. Limited vasculitis cases have been reported so far following vaccination against COVID-19. We present a case of cutaneous leukocytoclastic vasculitis (LCV) induced following the first dose of the ChAdOx1 nCoV-19 vaccine in an otherwise healthy individual.
2019年冠状病毒病（COVID-19）大流行是一个前所未有的事件，为了控制其传播并将损害降至最低，所有努力都立即展开。大规模疫苗接种被认为是应对这一全球性问题的一个有前景的解决方案。然而，鉴于疫苗生产的迫切需求，一些副作用可能在试验期间未出现，而只会在大规模接种期间出现。迄今为止，接种COVID-19疫苗后报告的血管炎病例有限。我们报告一例在一名原本健康的个体接种第一剂ChAdOx1 nCoV-19疫苗后诱发的皮肤白细胞破碎性血管炎（LCV）病例。
